Efficacy and safety of trellizumab combined with tegafur in second-line treatment of relapsed and metastatic esophageal squamous cell carcinoma
10.3760/cma.j.cn431274-20240514-00794
- VernacularTitle:替雷利珠单抗联合替吉奥二线治疗复发转移性食管鳞状细胞癌的效果及安全性
- Author:
Liping ZHONG
1
;
Bin WU
1
Author Information
1. 东南大学医学院附属南京同仁医院药学部，南京 211100
- Publication Type:Journal Article
- Keywords:
Antineoplastic combined chemotherapy protocols;
Esophageal squamous cell carcinoma;
Trelizumab;
Tegafur, gimeracil and oteracil potassium
- From:
Journal of Chinese Physician
2025;27(3):417-421
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To study the clinical efficacy and safety of trellizumab combined with tegafur in the treatment of relapsed and metastatic esophageal squamous cell carcinoma (ESCC).Methods:A total of 80 patients with relapsed and metastatic ESCC who were admitted to the Nanjing Tongren Hospital from January 2020 to January 2023 were prospectively selected and divided into tegafur group and combination group with 40 patients each according to random number table method. The tegafur group was treated with oxaliplatin combined with tegafur second-line therapy, and the combined group was treated with trellizumab based on the tegafur group. The short-term efficacy, adverse reactions and survival time of the tegafur group and the combination group were compared. Squamous cell carcinoma (SCC), lymphocyte-to-monocyte ratio (LMR), platelet-to-lymphocyte ratio (PLR), cellular immune function and quality of life were compared between the tegafur group and the combination group.Results:The total effective rate of the combined group was 32.50%(13/40) and 55.00%(22/40), and the median survival time was 10 and 14 months, respectively. The above indexes in the combined group were better than those in the tegafur group (all P<0.05). There were no significant differences in the incidence of leukopenia, neutropenia, alopecia, bone marrow suppression, bleeding and gastrointestinal reactions between the two groups (all P>0.05). After treatment, SCC levels in the Tegafur group and the combination group were (3.10±0.58)ng/ml and (2.24±0.63)ng/ml, PLR were 136.65±17.40 and 122.24±18.33, LMR were 4.28±0.78 and 5.33±0.85, respectively. The percentages of CD4 + T lymphocytes were (36.36±4.11)% and (41.18±4.05)%, the percentages of CD8 + T lymphocytes were (33.14±3.87)% and (28.46±3.77)%, and the CD4 + /CD8 + ratios were 1.10±0.14 and 1.45±0.19, respectively. The scores of the Quality of Life Questionnaire-Core 30 (QLQ-C30) were (63.25±7.01) and (67.14±6.84), and the scores of the Quality of Life Questionnaire-Oesophagus 18 (QLQ-OES18) were (50.24±6.98) and (45.30±7.11), respectively, with statistical significance (all P<0.05). Conclusions:The second-line treatment of recurrent and metastatic ESCC with trellizumab combined with tegafur can improve the short-term efficacy, SCC, LMR, PLR, enhance cellular immunity, improve quality of life, prolong survival, and have high safety.
